Fairmount Funds Management LLC - Q2 2023 holdings

$709 Million is the total value of Fairmount Funds Management LLC's 17 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was - .

 Value Shares↓ Weighting
IMGN NewIMMUNOGEN INC$113,778,4016,029,592
+100.0%
16.04%
KOD NewKODIAK SCIENCES INC$13,698,1911,985,245
+100.0%
1.93%
KNSA NewKINIKSA PHARMACEUTICALS LTD$9,918,783704,459
+100.0%
1.40%
AGLE NewAEGLEA BIOTHERAPEUTICS INC$4,261,9739,460,540
+100.0%
0.60%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-08-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ARGENX SE16Q3 20239.3%
AXSOME THERAPEUTICS INC15Q3 202324.6%
INSMED INC12Q3 202215.0%
ACADIA PHARMACEUTICALS INC12Q3 202215.5%
IOVANCE BIOTHERAPEUTICS INC12Q3 20229.4%
COGENT BIOSCIENCES INC12Q3 20237.2%
ENANTA PHARMACEUTICALS INC12Q3 20229.6%
ALLAKOS INC12Q3 20227.4%
AMARIN CORP PLC12Q3 202210.9%
VERONA PHARMA PLC12Q2 202311.9%

View Fairmount Funds Management LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Fairmount Funds Management LLC Q2 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Aeglea BioTherapeutics, Inc.June 30, 202317,230,54020.0%
Olema Pharmaceuticals, Inc.Sold outFebruary 14, 202300.0%
CATABASIS PHARMACEUTICALS INCJune 17, 20214,092,1665.3%
MIRAGEN THERAPEUTICS, INC.January 05, 2021967,67120.0%
Unum Therapeutics Inc.July 10, 20207,482,46020.0%

View Fairmount Funds Management LLC's complete significant-ownership history.

Latest filings
TypeFiled
42024-05-16
13F-HR2024-05-15
42024-04-25
SC 13D/A2024-04-25
42024-04-01
42024-04-01
42024-04-01
42024-04-01
SC 13D/A2024-04-01
SC 13D/A2024-04-01

View Fairmount Funds Management LLC's complete filings history.

Compare quarters

Export Fairmount Funds Management LLC's holdings